Items related to USDA, FDA, genetic engineering, and regulations associated with biotechnology in the Agriculture/Rural Development/Food and Drug Administration proposed Appropriation measures for FY 2026 (House/Senate).
2025 · 3rd Quarter (July 1 - Sep 30)
BIOTECHNOLOGY INNOVATION ORGANIZATION (FORMERLY BIOTECHNOLOGY INDUSTRY ORG.)
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 17, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL COUNSEL LLC
- Filing UUID
- c059b83a-71d1-4c8d-858e-e6b528668781
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Public health issues impacting patient access to treatments. Updates and reforms to regulation of treatment development and research.
Medicare Part B coverage and reimbursement issues for biotechnology treatments and issues related to the Medicare Part D coverage, including issues found in H.R. 1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21
Literal federal measure citations: H.R. 1
Legislative and regulatory issues affecting innovation, including vaccines.
Issues related to tarriffs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.